EA201201052A1 - Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk - Google Patents
Замещенные нафтиридины и их применение в качестве ингибиторов киназы sykInfo
- Publication number
- EA201201052A1 EA201201052A1 EA201201052A EA201201052A EA201201052A1 EA 201201052 A1 EA201201052 A1 EA 201201052A1 EA 201201052 A EA201201052 A EA 201201052A EA 201201052 A EA201201052 A EA 201201052A EA 201201052 A1 EA201201052 A1 EA 201201052A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alkyl
- substituted
- group
- ring
- naftyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
В заявке описаны новые замещенные нафтиридины формулы 1, а также их фармакологически приемлемые соли, диастереоизомеры, энантиомеры, рацематы, гидраты или сольватыв которой Rвыбран из группы, включающей -O-Rили -NRR, Rобозначает C-C-алкил, который замещен с помощью Rи R, Rвыбран из группы, включающей водород, разветвленный или линейный C-C-алкил, C-C-алкенил, -C-C-алкилен-О-C-C-алкил, C-C-галогеналкил, Rобозначает кольцо Xв котором n равно 0 или 1, иобозначает ординарную или двойную связь и в котором А, В, D, где кольцо X присоединено к молекуле в положении А, В, D или Е, где указанное кольцо X необязательно может быть дополнительно замещено 1, 2 или 3 остатками, каждый из которых по отдельности выбран из группы, включающей -оксогруппу, гидроксигруппу, -C-C-алкил, -C-C-галогеналкил, -O-C-C-алкил, -C-C-алканол и галоген, и где R, R, R, R, R, R, Rи Q могут обладать значениями, приведенными в п.1 формулы изобретения, а также фармацевтические композиции, содержащие эти соединения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10152159 | 2010-01-29 | ||
PCT/EP2011/050871 WO2011092128A1 (en) | 2010-01-29 | 2011-01-21 | Substituted naphthyridines and their use as syk kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201201052A1 true EA201201052A1 (ru) | 2013-02-28 |
Family
ID=42272624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201052A EA201201052A1 (ru) | 2010-01-29 | 2011-01-21 | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
Country Status (18)
Country | Link |
---|---|
US (2) | US8969568B2 (ru) |
EP (1) | EP2528915B1 (ru) |
JP (1) | JP5629331B2 (ru) |
KR (1) | KR20120125267A (ru) |
CN (1) | CN102822172A (ru) |
AR (1) | AR080074A1 (ru) |
AU (1) | AU2011209274B8 (ru) |
BR (1) | BR112012018865A2 (ru) |
CA (1) | CA2786245A1 (ru) |
CL (1) | CL2012001807A1 (ru) |
EA (1) | EA201201052A1 (ru) |
IL (1) | IL220553A0 (ru) |
MX (1) | MX2012008533A (ru) |
NZ (1) | NZ600857A (ru) |
TW (1) | TW201139435A (ru) |
UY (1) | UY33205A (ru) |
WO (1) | WO2011092128A1 (ru) |
ZA (1) | ZA201204793B (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8604049B2 (en) | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
NZ600857A (en) | 2010-01-29 | 2014-06-27 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors |
WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
MX336224B (es) | 2011-07-26 | 2016-01-12 | Boehringer Ingelheim Int | Quinolinas sustituidas y su uso como medicamentos. |
WO2014086032A1 (en) * | 2012-12-07 | 2014-06-12 | Hutchison Medipharma Limited | Substituted pyridopyrazines as syk inhibitors |
CN104812753A (zh) * | 2012-12-07 | 2015-07-29 | 和记黄埔医药(上海)有限公司 | 作为Syk抑制剂的取代吡啶并吡嗪类化合物 |
JP6434506B2 (ja) | 2013-10-21 | 2018-12-05 | ジェノスコ | 置換ピリミジン化合物およびsyk阻害剤としてのそれらの使用 |
EP3119765B1 (en) * | 2014-03-19 | 2019-07-17 | Boehringer Ingelheim International GmbH | Heteroaryl syk inhibitors |
EP3347353B1 (en) | 2015-09-11 | 2019-07-17 | Boehringer Ingelheim International GmbH | Pyrazolyl-substituted heteroaryls and their use as medicaments |
HUE061437T2 (hu) * | 2015-10-23 | 2023-06-28 | Navitor Pharm Inc | A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai |
US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN114315747A (zh) * | 2020-09-30 | 2022-04-12 | 山东润博生物科技有限公司 | 一种5,5-二甲基异噁唑烷-3-硫酮的制备方法 |
KR20220138654A (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | 당뇨병의 예방 또는 치료용 화합물 |
KR20220138655A (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | 신장 질환의 예방 또는 치료용 화합물 |
CN113735791A (zh) * | 2021-10-14 | 2021-12-03 | 杭州欧晨科技有限公司 | 一种3-溴-5,5-二甲基-4,5-二氢异噁唑的合成方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
US4260759A (en) | 1969-04-14 | 1981-04-07 | Schering-Corporation | Process for preparing 1-aminonaphthyridines |
US3928367A (en) | 1969-04-14 | 1975-12-23 | Schering Corp | 1-Amino naphthyridines |
US4115395A (en) | 1975-11-12 | 1978-09-19 | Schering Corporation | 1-Aminonaphthyridines |
DE3027619A1 (de) | 1979-07-25 | 1981-02-19 | Sandoz Ag | 6-alkyl-7-phenyl-1,6-naphtyradin- 5(6h)-on-derivate |
US4329349A (en) | 1979-07-25 | 1982-05-11 | Sandoz, Inc. | 6-C1-4 Alkyl-7-phenyl or substituted phenyl-1,6-naphthyridine-5(6H)-ones |
ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
WO2001052902A1 (en) | 2000-01-24 | 2001-07-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of inducible nitric oxide synthase expression |
GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
AR035851A1 (es) | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
MEP40008A (en) | 2000-10-12 | 2011-02-10 | Boehringer Ingelheim Pharma | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
RS50441B (sr) | 2001-06-22 | 2010-03-02 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg. | Kristalni antiholinergik, postupak za njegovo pripremanje i njegova primena u proizvodnji leka |
DE10292982D2 (de) * | 2001-07-04 | 2004-07-01 | Braincom Ag | Flächenheizung, Verfahren zu deren Herstellung und heizbarer Gegenstand sowie Sitzbelegungserkennung, Sitz damit und Sitzbelegungserkennungsverfahren |
US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
JP2006519846A (ja) | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター:使用および合成の方法 |
CL2004000985A1 (es) | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
CA2542105C (en) | 2003-10-08 | 2011-08-02 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
WO2008051757A1 (en) | 2006-10-20 | 2008-05-02 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
EP2094276A4 (en) * | 2006-12-20 | 2011-01-05 | Abbott Lab | ANTIVIRAL COMPOUNDS |
US8053440B2 (en) * | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
JP5377332B2 (ja) | 2007-02-06 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法 |
WO2009038412A2 (en) | 2007-09-21 | 2009-03-26 | Lg Life Sciences, Ltd. | Beta-secretase inhibiting compounds |
MX2010003001A (es) | 2007-09-27 | 2010-04-01 | Hoffmann La Roche | Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a. |
US8604049B2 (en) | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
EP2324022A1 (de) | 2008-08-05 | 2011-05-25 | Boehringer Ingelheim International GmbH | Substituierte naphthyridine und ihre verwendung als arzneimittel |
FR2949465B1 (fr) | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
NZ600857A (en) | 2010-01-29 | 2014-06-27 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
MX336224B (es) | 2011-07-26 | 2016-01-12 | Boehringer Ingelheim Int | Quinolinas sustituidas y su uso como medicamentos. |
EP2736900A1 (en) | 2011-07-26 | 2014-06-04 | Grünenthal GmbH | Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands |
-
2011
- 2011-01-21 NZ NZ60085711A patent/NZ600857A/en not_active IP Right Cessation
- 2011-01-21 CN CN2011800165422A patent/CN102822172A/zh active Pending
- 2011-01-21 BR BR112012018865A patent/BR112012018865A2/pt not_active IP Right Cessation
- 2011-01-21 KR KR20127019984A patent/KR20120125267A/ko not_active Application Discontinuation
- 2011-01-21 WO PCT/EP2011/050871 patent/WO2011092128A1/en active Application Filing
- 2011-01-21 MX MX2012008533A patent/MX2012008533A/es not_active Application Discontinuation
- 2011-01-21 EA EA201201052A patent/EA201201052A1/ru unknown
- 2011-01-21 JP JP2012550404A patent/JP5629331B2/ja active Active
- 2011-01-21 CA CA 2786245 patent/CA2786245A1/en not_active Abandoned
- 2011-01-21 AU AU2011209274A patent/AU2011209274B8/en not_active Expired - Fee Related
- 2011-01-21 EP EP11700849.0A patent/EP2528915B1/en active Active
- 2011-01-26 US US13/013,973 patent/US8969568B2/en active Active
- 2011-01-28 UY UY33205A patent/UY33205A/es not_active Application Discontinuation
- 2011-01-28 AR ARP110100305 patent/AR080074A1/es unknown
- 2011-01-28 TW TW100103483A patent/TW201139435A/zh unknown
-
2012
- 2012-06-21 IL IL220553A patent/IL220553A0/en unknown
- 2012-06-27 ZA ZA2012/04793A patent/ZA201204793B/en unknown
- 2012-07-04 CL CL2012001807A patent/CL2012001807A1/es unknown
-
2015
- 2015-01-08 US US14/592,301 patent/US9187478B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2528915B1 (en) | 2015-10-28 |
US8969568B2 (en) | 2015-03-03 |
AR080074A1 (es) | 2012-03-14 |
BR112012018865A2 (pt) | 2016-04-12 |
CL2012001807A1 (es) | 2012-10-12 |
EP2528915A1 (en) | 2012-12-05 |
ZA201204793B (en) | 2013-02-27 |
US20120028939A1 (en) | 2012-02-02 |
MX2012008533A (es) | 2012-08-31 |
CA2786245A1 (en) | 2011-08-04 |
AU2011209274A1 (en) | 2012-07-19 |
WO2011092128A1 (en) | 2011-08-04 |
UY33205A (es) | 2011-08-31 |
US9187478B2 (en) | 2015-11-17 |
IL220553A0 (en) | 2012-08-30 |
US20150126503A1 (en) | 2015-05-07 |
CN102822172A (zh) | 2012-12-12 |
JP5629331B2 (ja) | 2014-11-19 |
AU2011209274B8 (en) | 2015-08-13 |
AU2011209274A8 (en) | 2015-08-13 |
JP2013518073A (ja) | 2013-05-20 |
KR20120125267A (ko) | 2012-11-14 |
TW201139435A (en) | 2011-11-16 |
NZ600857A (en) | 2014-06-27 |
AU2011209274B2 (en) | 2015-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201201052A1 (ru) | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk | |
EA200970207A1 (ru) | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов | |
EA201700230A1 (ru) | Определенные аминопиридины, композиции на их основе и способы их применения | |
EA201390766A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ | |
EA201201377A1 (ru) | Определенные аминопиридазины, композиции на их основе и способы их использования | |
EA201390877A1 (ru) | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение | |
RS53301B (en) | TIOACETATE COMPOUNDS, COMPOSITIONS AND USE PROCEDURES | |
EA200900213A1 (ru) | Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич | |
EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
WO2008115098A3 (fr) | 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation | |
WO2014008458A3 (en) | N-substituted benzamides and methods of use thereof | |
RS53503B1 (en) | AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR | |
EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
EA201291376A1 (ru) | Новые кальциевые соли соединения в качестве противовоспалительных, иммуномодулирующих и антипролиферативных агентов | |
EA201190293A1 (ru) | Пролекарства триптолида | |
EA201101097A1 (ru) | Новые микробиоциды | |
AR081964A1 (es) | Derivados aminoester de alcaloides y composiciones medicinales de los mismos | |
AR076709A1 (es) | Piperidinas sustituidas como antagonistas de par-1 y un procedimiento para su preparacion | |
PE20081376A1 (es) | Derivados de pirrolizina, indolizina y quinolizina, su preparacion y su aplicacion en terapeutica |